AIM
BMY.RT

Achmea Investment Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Achmea Investment Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-87,695
Closed -$60K – 518
2020
Q4 		$60K Hold
87,695
– – ﹤0.01% 477
2020
Q3 		$197K Buy
+87,695
New +$250K 0.01% 476
2020
Q2 		– Sell
-88,571
Closed -$337K – 329
2020
Q1 		$337K Buy
+88,571
New +$292K 0.02% 215

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Achmea Investment Management's BMY.RT Position: Q1 2021 in Review

Achmea Investment Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 87,695 shares — an estimated $60K sold.

Achmea Investment Management first reported a position in BMY.RT in Q1 2020 and held it in 3 quarters. The position peaked at $337K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Achmea Investment Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Achmea Investment Management sold 87,695 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $60K.
  • Achmea Investment Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 3 quarters.
  • Achmea Investment Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $337K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Achmea Investment Management's 13F filing for Q1 2021, filed 11 May 2021.